medigraphic.com

2019, Número 3

<< Anterior Siguiente >>

Cuba y Salud 2019; 14 (3)


Neuroinflamación y Enfermedad de Parkinson

Pavón FN, Lorigados PL

Idioma: Español
Referencias bibliográficas: 50
Paginas: 44-49
Archivo PDF: 303.95 Kb.


RESUMEN

Objetivo: revisar y discutir el papel que juegan los mecanismos neuroinflamatorios en la Enfermedad de Parkinson y en los modelos animales de esta enfermedad.
Desarrollo: se muestra un grupo de evidencias que relacionan la activación de la microglia y los procesos de degeneración de las células dopaminérgicas. Los linfocitos T periféricos se infiltran en el parénquima del Sistema Nervioso Central en el sitio de la lesión neuronal tanto en humanos con Enfermedad de Parkinson como en modelos de parkinsonismo. La respuesta inmune mediada por las células contribuye a la degeneración de las células dopaminérgicas a través de los mecanismos citotóxico dependiente de la unión Fas/ FasL. Se discute el papel de varias hipótesis que pudieran estar relacionadas con los cambios en la respuesta inmunológica.
Conclusiones: los mecanismos aquí discutidos permiten respaldar el uso potencial de los fármacos inmunomoduladores como agentes neuroprotectores para retrasar el proceso degenerativo nigroestriatal.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Calabrese V, Santoro A, Monti D, Crupi R, Di Paola R, Latteri S, et al. Aging and Parkinson’s disease: inflammaging, neuroinflammation and biological remodeling as key factors in pathogenesis. Free Radical Biology and Medicine. 2018;115:80-91.

  2. Uysal-Cantürk P, Hanağası HA, Bilgiç B, Gürvit H, Emre M. An assessment of Movement Disorder Society Task Force diagnostic criteria for mild cognitive impairment in Parkinson’s disease. European journal of neurology. 2018;25(1):148-53.

  3. Postuma RB, Poewe W, Litvan I, Lewis S, Lang AE, Halliday G, et al. Validation of the MDS clinical diagnostic criteria for Parkinson’s disease. Movement Disorders. 2018;33(10):1601-8.

  4. King E, O’Brien J, Donaghy P, Williams-Gray CH, Lawson RA, Morris CM, et al. Inflammation in mild cognitive impairment due to Parkinson’s disease, Lewy body disease, and Alzheimer’s disease. International journal of geriatric psychiatry. 2019;34(8):1244-50.

  5. Nutt JG. Motor subtype in Parkinson’s disease: Different disorders or different stages of disease? Movement Disorders. 2016;31(7):957-61.

  6. Dickson DW. Neuropathology of Parkinson disease. Parkinsonism & related disorders. 2018;46:S30-S3.

  7. Rocha EM, De Miranda B, Sanders LH. Alpha-synuclein: pathology, mitochondrial dysfunction and neuroinflammation in Parkinson’s disease. Neurobiology of disease. 2018;109:249-57.

  8. García-González P, Cabral-Miranda F, Hetz C, Osorio F. Interplay Between the Unfolded Protein Response and Immune Function in the Development of Neurodegenerative Diseases. Frontiers in immunology. 2018;9:2541.

  9. Joe E-H, Choi D-J, An J, Eun J-H, Jou I, Park S. Astrocytes, microglia, and Parkinson’s disease. Experimental neurobiology. 2018;27(2):77-87.

  10. Aliseychik M, Andreeva T, Rogaev E. Immunogenetic Factors of Neurodegenerative Diseases: The Role of HLA Class II. Biochemistry (Moscow). 2018;83(9):1104-16.

  11. Schröder JB, Pawlowski M, Gross CC, Wiendl H, Meuth SG, Ruck T, et al. Immune cell activation in the cerebrospinal fluid of patients with Parkinson’s disease. Frontiers in neurology. 2018;9:1081.

  12. Li D, Song X, Huang H, Huang H, Ye Z. Association of Parkinson’s disease-related pain with plasma interleukin-1, interleukin-6, interleukin-10, and tumour necrosis factor-α. Neuroscience letters. 2018;683:181-4.

  13. Sadanand A, Janardhanan A, Vanisree A, Pavai T. Neurotrophin expression in lymphocytes: a powerful indicator of degeneration in Parkinson’s disease, amyotrophic lateral sclerosis and ataxia. Journal of Molecular Neuroscience. 2018;64(2):224-32.

  14. Garretti F, Agalliu D, Lindestam Arlehamn CS, Sette A, Sulzer D. Autoimmunity in Parkinson’s disease: the role of α-synuclein-specific T cells. Frontiers in immunology. 2019;10:303.

  15. Xue X, Zhang W, Zhu J, Chen X, Zhou S, Xu Z, et al. Aquaporin-4 deficiency reduces TGF-β1 in mouse midbrains and exacerbates pathology in experimental Parkinson’s disease. Journal of cellular and molecular medicine. 2019;23(4):2568-82.

  16. Harms AS, Barnum CJ, Ruhn KA, Varghese S, Treviño I, Blesch A, et al. Delayed dominant-negative TNF gene therapy halts progressive loss of nigral dopaminergic neurons in a rat model of Parkinson’s disease. Molecular Therapy. 2011;19(1):46-52.

  17. Brochard V, Combadière B, Prigent A, Laouar Y, Perrin A, Beray-Berthat V, et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. The Journal of clinical investigation. 2008;119(1).

  18. Hayley S, Crocker SJ, Smith PD, Shree T, Jackson-Lewis V, Przedborski S, et al. Regulation of dopaminergic loss by Fas in a 1-methyl-4- phenyl-1, 2, 3, 6-tetrahydropyridine model of Parkinson’s disease. Journal of Neuroscience. 2004;24(8):2045-53.

  19. Joshi N, Singh S. Updates on immunity and inflammation in Parkinson disease pathology. Journal of neuroscience research. 2018;96(3):379- 90.

  20. Pushpavathi SG, Duraisamy K, Ahmed ME, Thangavel R, Dubova I, Mentor S, et al. Glia Maturation Factor Dependent Mast Cell Activation and Calpain 1 Synergize Dopaminergic Neuronal Loss and Behavioral Deficits in an MPTP Mouse Model of Parkinson’s Disease. The FASEB Journal. 2019;33(1_supplement):791.7-.7.

  21. Herlofson K, Heijnen C, Lange J, Alves G, Tysnes OB, Friedman J, et al. Inflammation and fatigue in early, untreated Parkinson’s Disease. Acta Neurologica Scandinavica. 2018;138(5):394-9.

  22. Tansey MG, Romero-Ramos M. Immune system responses in Parkinson’s disease: Early and dynamic. European Journal of Neuroscience. 2019;49(3):364-83.

  23. Zhang H, Zhu L, Sun L, Zhi Y, Ding J, Yuan Y-S, et al. Phosphorylated α-synuclein deposits in sural nerve deriving from Schwann cells: A biomarker for Parkinson’s disease. Parkinsonism & related disorders. 2019;60:57-63.

  24. Kouchaki E, Kakhaki RD, Tamtaji OR, Dadgostar E, Behnam M, Nikoueinejad H, et al. Increased serum levels of TNF-α and decreased serum levels of IL-27 in patients with Parkinson disease and their correlation with disease severity. Clinical neurology and neurosurgery. 2018;166:76-9.

  25. Orr CF, Rowe DB, Mizuno Y, Mori H, Halliday GM. A possible role for humoral immunity in the pathogenesis of Parkinson’s disease. Brain. 2005;128(11):2665-74.

  26. Hunot S, Hirsch E. Neuroinflammatory processes in Parkinson’s disease. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society. 2003;53(S3):S49-S60.

  27. Blagosklonny MV. A node between proliferation, apoptosis, and growth arrest. Bioessays. 1999;21(8):704-9.

  28. Camargo N, Goudriaan A, van Deijk A-LF, Otte WM, Brouwers JF, Lodder H, et al. Oligodendroglial myelination requires astrocyte-derived lipids. PLoS biology. 2017;15(5):e1002605.

  29. Spielman LJ, Gibson DL, Klegeris A. Incretin hormones regulate microglia oxidative stress, survival and expression of trophic factors. European journal of cell biology. 2017;96(3):240-53.

  30. Tome D, Pais Fonseca C, Lopes Campos F, Baltazar G. Role of Neurotrophic Factors in Parkinson’s Disease. Current pharmaceutical design. 2017;23(5):809-38.

  31. Bartus RT, Johnson Jr EM. Clinical tests of neurotrophic factors for human neurodegenerative diseases, part 2: Where do we stand and where must we go next? Neurobiology of disease. 2017;97:169-78.

  32. Shinoda Y, Sadakata T, Yagishita K, Kinameri E, Katoh-Semba R, Sano Y, et al. Aspects of excitatory/inhibitory synapses in multiple brain regions are correlated with levels of brain-derived neurotrophic factor/neurotrophin-3. Biochemical and biophysical research communications. 2019;509(2):429-34.

  33. Moalem G, Gdalyahu A, Shani Y, Otten U, Lazarovici P, Cohen IR, et al. Production of neurotrophins by activated T cells: implications for neuroprotective autoimmunity. Journal of autoimmunity. 2000;15(3):331-45.

  34. Torcia M, De Chiara G, Nencioni L, Ammendola S, Labardi D, Lucibello M, et al. Nerve growth factor inhibits apoptosis in memory B lymphocytes via inactivation of p38 MAPK, prevention of Bcl-2 phosphorylation, and cytochrome c release. Journal of Biological Chemistry. 2001;276(42):39027-36.

  35. Flügel A, Matsumuro K, Neumann H, Klinkert WE, Birnbacher R, Lassmann H, et al. Anti-inflammatory activity of nerve growth factor in experimental autoimmune encephalomyelitis: inhibition of monocyte transendothelial migration. European journal of immunology. 2001;31(1):11- 22.

  36. Yauger YJ, Bermudez S, Moritz KE, Glaser E, Stoica B, Byrnes KR. Iron accentuated reactive oxygen species release by NADPH oxidase in activated microglia contributes to oxidative stress in vitro. Journal of neuroinflammation. 2019;16(1):41.

  37. Hickman S, Izzy S, Sen P, Morsett L, El Khoury J. Microglia in neurodegeneration. Nature neuroscience. 2018;21(10):1359.

  38. Lorigados Pedre L PFN, Alvarez González L, McRae A, Serrano Sánchez T, Blanco Lescano L, Macías González R. Nerve growth factor levels in Parkinson disease and experimental parkinsonian rats. Brain Res. 2002;952(1):122-7.

  39. Minnella AM, Zhao JX, Jiang X, Jakobsen E, Lu F, Wu L, et al. Excitotoxic superoxide production and neuronal death require both ionotropic and non-ionotropic NMDA receptor signaling. Scientific reports. 2018;8(1):17522.

  40. Chen X, Yu C, Guo M, Zheng X, Ali S, Huang H, et al. Down-Regulation of m6A mRNA Methylation Is Involved in Dopaminergic Neuronal Death. ACS chemical neuroscience. 2019;10(5):2355-63.

  41. Hu H-J, Song M. Disrupted ionic homeostasis in ischemic stroke and new therapeutic targets. Journal of Stroke and Cerebrovascular Diseases. 2017;26(12):2706-19.

  42. Chen Z, Trapp BD. Microglia and neuroprotection. Journal of Neurochemistry. 2016;136:10-7.

  43. Pal R, Tiwari PC, Nath R, Pant KK. Role of neuroinflammation and latent transcription factors in pathogenesis of Parkinson’s disease. Neurological research. 2016;38(12):1111-22.

  44. Choi D-J, An J, Jou I, Park SM, Joe E-H. A Parkinson’s disease gene, DJ-1, regulates anti-inflammatory roles of astrocytes through prostaglandin D2 synthase expression. Neurobiology of disease. 2019;127:482-91.

  45. Corwin C, Nikolopoulou A, Pan AL, Nunez-Santos M, Vallabhajosula S, Serrano P, et al. Prostaglandin D2/J2 signaling pathway in a rat model of neuroinflammation displaying progressive parkinsonian-like pathology: potential novel therapeutic targets. Journal of neuroinflammation. 2018;15(1):272.

  46. Niranjan R, Mishra KP, Thakur AK. Inhibition of Cyclooxygenase-2 (COX-2) Initiates Autophagy and Potentiates MPTP-Induced Autophagic Cell Death of Human Neuroblastoma Cells, SH-SY5Y: an Inside in the Pathology of Parkinson’s Disease. Molecular neurobiology. 2018;55(10):8038- 50.

  47. Tiwari HS, Misra UK, Kalita J, Mishra A, Shukla S. Oxidative stress and glutamate excitotoxicity contribute to apoptosis in cerebral venous sinus thrombosis. Neurochemistry international. 2016;100:91-6.

  48. Wen Z, Zhang J, Tang P, Tu N, Wang K, Wu G. Overexpression of miR‑185 inhibits autophagy and apoptosis of dopaminergic neurons by regulating the AMPK/mTOR signaling pathway in Parkinson’s disease. Molecular medicine reports. 2018;17(1):131-7.

  49. Gadicherla AK, Wang N, Bulic M, Agullo-Pascual E, Lissoni A, De Smet M, et al. Mitochondrial Cx43 hemichannels contribute to mitochondrial calcium entry and cell death in the heart. Basic research in cardiology. 2017;112(3):27.

  50. Lieberman OJ, Choi SJ, Kanter E, Saverchenko A, Frier MD, Fiore GM, et al. α-Synuclein-dependent calcium entry underlies differential sensitivity of cultured SN and VTA dopaminergic neurons to a Parkinsonian neurotoxin. eNeuro. 2017;4(6):ENEURO.0167-17.




2020     |     www.medigraphic.com